研究评估奥妥珠单抗（odronextamab）治疗复发 / 难治性弥漫大 B 细胞淋巴瘤（R/R DLBCL），疗效佳且安全性可控。 正在进行的 2 期多队列 ELM-2 研究，评估了 CD20×CD3 双特异性抗体奥妥珠单抗（odronextamab）对经过≥2 线治疗的复发 / 难治性（R/R）B 细胞非霍奇金淋巴瘤 ...

Ordspono (odronextamab) has been cleared by the European Commission to treat adults with relapsed/refractory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL) who have progressed ...

A year after the FDA rejected its marketing application for CD20xCD3 bispecific antibody odronextamab to treat two common forms of non-Hodgkin lymphoma (NHL), Regeneron has refiled the drug for ...